Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
GAITHERSBURG, Md., Feb. 22, 2016 -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its fourth quarter and full year 2015 financial and operating results prior to the open of U.S. financial markets on Monday, February 29, 2016.
Management will host a conference call to discuss the quarterly and year-end financial results and provide an update on corporate activities.
Conference call details are as follows:
| Date: | February 29, 2016 | |
| Time: | 8:00 am U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Via web: | www.novavax.com, “Investors”/ “Events” | |
Conference call replay:
| Dates: | Starting at 11:00 am ET, February 29, 2016 until midnight March 7, 2016 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 45346424 | |
| Via web: | www.novavax.com, “Investors”/ “Events” | |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations [email protected] 240-268-2000
